ALZAMEND NEURO, INC. Gain (Loss) on Extinguishment of Debt
ALZAMEND NEURO, INC. (ALZN) reported Gain (Loss) on Extinguishment of Debt of $4.00 thousand for the 12-month period ending 2022-04-30, per its 10-K filed 2023-07-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:GainsLossesOnExtinguishmentOfDebt · last filed 2023-07-27
- ALZAMEND NEURO, INC. gain (loss) on extinguishment of debt for the quarter ending 2021-04-30 was $0.00.
- ALZAMEND NEURO, INC. gain (loss) on extinguishment of debt for the quarter ending 2021-01-31 was $62.42K.
- ALZAMEND NEURO, INC. gain (loss) on extinguishment of debt for fiscal 2022 was $4.00K, a 93.59% decline from fiscal 2021.
- ALZAMEND NEURO, INC. gain (loss) on extinguishment of debt for fiscal 2021 was $62.42K.
| Period end | Gain (Loss) on Extinguishment of Debt 3 month | Gain (Loss) on Extinguishment of Debt 6 month | Gain (Loss) on Extinguishment of Debt 9 month | Gain (Loss) on Extinguishment of Debt 12 month |
|---|---|---|---|---|
| 2022-04-30 | $4.00K 10-K · filed 2023-07-27 | |||
| 2021-04-30 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2022-07-19 | $62.42K derived: sum of 2 quarters · filed 2022-07-19 | $62.42K 10-K · filed 2022-07-19 | |
| 2021-01-31 | $62.42K 10-Q · filed 2022-03-15 | $62.42K 10-Q · filed 2022-03-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Traws Pharma, Inc. (TRAW) | United States | $0.009B | -0.58 |
| FibroBiologics, Inc. (FBLG) | United States | $0.009B | -0.27 |
| Imunon, Inc. (IMNN) | United States | $0.008B | -0.56 |
| SOLIGENIX, INC. (SNGX) | United States | $0.008B | |
| EXICURE, INC. (XCUR) | United States | $0.008B | -1.54 |
| Ensysce Biosciences, Inc. (ENSC) | United States | $0.008B | -0.37 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| InMed Pharmaceuticals Inc. (INM) | $0.008B | -0.65 | |
| Apimeds Pharmaceuticals US, Inc. (APUS) | United States | $0.008B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B |